Business · 17/11/20261 min read
Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026
Summary
Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14 Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of...